- •Preface
- •Contents
- •Contributors
- •1: Living with Diabetic Retinopathy: The Patient’s View
- •My Patient Experience
- •Others’ Experiences
- •Photos of the Meaning of Diabetes
- •References
- •2: Diabetic Retinopathy Screening: Progress or Lack of Progress
- •Definitions of Screening for Diabetic Retinopathy
- •Studies Reporting the Prevalence of Diabetic Retinopathy
- •Reports on Blindness and Visual Impairment
- •Is There Evidence That Treatment for Sight-Threatening Diabetic Retinopathy Is Effective and Agreed Universally?
- •The Evidence That Diabetic Retinopathy Can Be Prevented or the Rate of Deterioration Reduced by Improved Control of Blood Glucose, Blood Pressure and Lipid Levels, and by Giving Up Smoking
- •The Evidence that Laser Treatment Is Effective
- •The Evidence That Vitrectomy for More Advanced Disease Is Effective
- •Progress of Lack of Progress in Screening for Diabetic Retinopathy in Different Parts of the World
- •References
- •3: Functional/Neural Mapping Discoveries in the Diabetic Retina: Advancing Clinical Care with the Multifocal ERG
- •Introduction
- •The Diabetes Epidemic
- •Current Treatment Focus
- •Vasculopathy and Neuropathy of the Retina
- •The Early Efforts
- •Some Breakthroughs
- •Predictive Models of Visible Retinopathy Onset at Specific Locations
- •How Is the mfERG Measured and What is it Measuring?
- •Where Are These Neural Signals Generated in the Retina?
- •Some Key Results
- •Adolescents and Adult Diabetes
- •Type 1 vs. Type 2: Differences in Retinal Function
- •References
- •4: Corneal Diabetic Neuropathy
- •Introduction
- •Corneal Confocal Microscopy
- •Corneal Nerves and Diabetes
- •Conclusion
- •References
- •5: Clinical Phenotypes of Diabetic Retinopathy
- •Natural History
- •MA Formation and Disappearance Rates
- •Alteration of the Blood–Retinal Barrier
- •Retinal Capillary Closure
- •Multimodal Macula Mapping
- •Clinical Retinopathy Phenotypes
- •Relevance for Clinical Trial Design
- •Relevance for Clinical Management
- •Targeted Treatments
- •References
- •6: Visual Psychophysics in Diabetic Retinopathy
- •Introduction
- •Visual Acuity
- •Color Vision
- •Contrast Sensitivity
- •Macular Recovery Function (Nyctometry)
- •Perimetry
- •Microperimetry (Fundus-Related Perimetry)
- •Conclusion
- •References
- •7: Mechanisms of Blood–Retinal Barrier Breakdown in Diabetic Retinopathy
- •The Protective Barriers of the Retina
- •The Inner and the Outer BRB
- •Inflammation and BRB Permeability
- •Leukocyte Mediators of Vascular Leakage
- •Other Mediators of Leukocyte Recruitment in DR
- •Structural Compromise of the BRB
- •Vascular Endothelial Growth Factor
- •Anti-VEGF Properties of Natriuretic Peptides
- •Proposed Model of BRB Breakdown in DR
- •Key Role of AZ in VEGF-Induced Leakage
- •Azurocidin Inhibition Prevents Diabetic Retinal Vascular Leakage
- •References
- •8: Molecular Regulation of Endothelial Cell Tight Junctions and the Blood-Retinal Barrier
- •The Blood-Retinal Barrier
- •The Retinal Vascular Barrier
- •The Junctional Complex
- •ZO Proteins
- •Claudins
- •Junctional Adhesion Molecules
- •Occludin and Tricellulin
- •Vascular Permeability in Diabetic Retinopathy
- •VEGF-Induced Regulation of Endothelial Permeability
- •Occludin Phosphorylation and Permeability
- •Protein Kinase C in Regulation of Barrier Properties
- •Conclusions
- •References
- •9: Capillary Degeneration in Diabetic Retinopathy
- •Vascular Nonperfusion in Diabetes: Mechanisms
- •Molecular Causes of Capillary Degeneration
- •Unexplained Aspects of Diabetes-Induced Degeneration of Retinal Capillaries
- •What Is the Relation Between the Retinal Vasculature and Neuronal Retina Structure and Function in Diabetes?
- •Conclusion
- •References
- •10: Proteases in Diabetic Retinopathy
- •Proteases in Retinal Vasculature
- •Extracellular Proteases
- •Urokinase Plasminogen Activator System (uPA/uPAR System)
- •Matrix Metalloproteinases
- •Endogenous Inhibitors of Proteases
- •Tissue Inhibitors of Metalloproteinases (TIMPs)
- •Plasminogen Activator Inhibitors (PAI)
- •Proteases in Retinal Neovascularization
- •Tissue Inhibitor of Matrix Metalloproteinases in Retinal Neovascularization
- •Inhibition of Retinal Angiogenesis by MMP Inhibitors
- •Inhibition of Retinal Angiogenesis by Inhibitors of the uPA/uPAR System
- •Proteases in Diabetic Macular Edema
- •Conclusion
- •References
- •11: Proteomics in the Vitreous of Diabetic Retinopathy Patients
- •Introduction
- •Vitreous Anatomy
- •A Candidate Approach
- •Proteomic Approaches
- •Vitreous Acquisition
- •Sample Pre-Fractionation
- •Mass Spectrometry
- •Spectral Analysis
- •Data Analysis
- •The Vitreous Proteome
- •2-DE-Based Proteomics
- •1-DE-Based Proteomics
- •Summary and Conclusions
- •References
- •12: Neurodegeneration in Diabetic Retinopathy
- •Introduction
- •Histological Evidence
- •Early Pathology Studies
- •Histological Evidence of Apoptosis
- •Gross Morphological Changes in the Retina
- •Reductions in Numbers of Surviving Amacrine Cells
- •Retinal Ganglion Cell Loss
- •Abnormalities in Ganglion Cell Morphology
- •Centrifugal Axon Abnormalities
- •Nerve Fiber Layer Thickness
- •Biochemical Evidence of Neurodegeneration and Cell Death
- •Functional Evidence of Neurodegenerative Changes
- •Electrophysiological Evidence for Neurodegeneration
- •Optic Nerve Retrograde Transport
- •Other Changes in Visual Function
- •Summary and Conclusions
- •References
- •13: Glucose-Induced Cellular Signaling in Diabetic Retinopathy
- •Introduction
- •Cellular Targets in DR
- •Endothelial Cell (EC) Dysfunction
- •Endothelial-Pericyte Interactions
- •Endothelial-Matrix Interactions
- •Signaling Mechanisms in DR
- •Altered Vasoactive Factors
- •Alteration of Metabolic Pathways
- •Polyol Pathway
- •Hexosamine Pathway
- •Protein Kinase C Pathway
- •Activation of Other Protein Kinases
- •Mitogen-Activated Protein Kinase (MAPK)
- •Increased Oxidative Stress
- •Protein Glycation
- •Aberrant Expression of Growth Factors
- •Transcription Factors
- •Transcription Regulators
- •Concluding Remarks
- •References
- •Introduction
- •The Growth-Hormone/Insulin-Like Growth Factor Pathway in Proliferative Retinopathies
- •Proliferative Diabetic Retinopathy (PDR)
- •Retinopathy of Prematurity (ROP)
- •Animal Models of Proliferative Retinopathies
- •IGFBP-3 as a Regulator of the Growth-Hormone/ Insulin-Like Growth Factor Pathway
- •Conclusion
- •References
- •15: Neurotrophic Factors in Diabetic Retinopathy
- •Diabetic Retinopathy
- •Neurotrophic Factors
- •Neurotrophins and Others
- •Nerve Growth Factor
- •Glial-Cell-Derived Neurotrophic Factor
- •Ciliary Neurotrophic Factor
- •Anti-angiogenic Neurotrophic Factors
- •Pigment-Epithelium-Derived Factor
- •SERPINA3K
- •Brain-Derived Neurotrophic Factor
- •Fibroblast Growth Factors
- •Insulin and Insulin-Like Growth Factor 1
- •Erythropoietin
- •Vascular Endothelial Growth Factor
- •Neurotrophic Factors and the Future of DR Research
- •References
- •16: The Role of CTGF in Diabetic Retinopathy
- •Introduction
- •ECM Remodeling and Wound Healing Mechanisms in Diabetic Retinopathy
- •ECM Remodeling in PCDR
- •Wound Healing Mechanisms in PDR
- •CTGF Structure and Function
- •CTGF in the Eye
- •CTGF in Ocular Fibrosis
- •CTGF in Ocular Angiogenesis
- •CTGF in Diabetic Retinopathy
- •CTGF in BL Thickening in PCDR
- •AGEs and CTGF in BL Thickening in PCDR
- •Role of VEGF in BL Thickening
- •BL Thickening in Diabetic CTGF-Knockout Mice
- •CTGF in PDR
- •Role of CTGF and VEGF in the “Angiofibrotic Switch” in PDR
- •Conclusions
- •References
- •17: Ranibizumab and Other VEGF Antagonists for Diabetic Macular Edema
- •Introduction
- •Pathogenesis of DME and Current Standard of Care
- •Ranibizumab for DME
- •Pegaptanib for DME
- •Bevacizumab for DME
- •VEGF Trap-Eye for DME
- •Other Considerations in the Management of DME
- •Combination Treatment for DME
- •DME and Quality of Life
- •Conclusions
- •References
- •18: Neurodegeneration, Neuropeptides, and Diabetic Retinopathy
- •Introduction
- •Neuropeptides Involved in the Pathogenesis of DR
- •Glutamate
- •Angiotensin II
- •Pigment Epithelial-Derived Factor
- •Somatostatin
- •Erythropoietin
- •Docosahexaenoic Acid and Neuroprotectin D1
- •Brain-Derived Neurotrophic Factor
- •Glial Cell Line-Derived Neurotrophic Factor
- •Ciliary Neurotrophic Factor
- •Adrenomedullin
- •Concluding Remarks and Therapeutic Implications
- •References
- •19: Glial Cell–Derived Cytokines and Vascular Integrity in Diabetic Retinopathy
- •Introduction
- •The BRB Functional Unit Composed of Glial and Endothelial Cells
- •Tight Junctions Between Endothelial Cells Are Substantial Barrier of the BRB
- •Major Cytokines Derived from Glial Cells Affecting Tight Junctions of the BRB
- •VEGF
- •GDNF
- •APKAP12
- •A Possible Treatment of the Retinopathy with Retinoic Acid Analogues
- •Conclusion
- •References
- •20: Impact of Islet Cell Transplantation on Diabetic Retinopathy in Type 1 Diabetes
- •Introduction
- •What Are the Benefits and Risks of Reducing Blood Glucose?
- •On Average, 3 Years Was Required to Demonstrate the Beneficial Effect of Intensive Treatment
- •The Earlier in the Course of Diabetes That Intensive Therapy Is Initiated, Even Before the Onset of Retinopathy, the Greater the Long-Term Benefits
- •Risk Reduction in the Primary Prevention Cohort
- •Risk Reduction in the Secondary Prevention Cohort
- •There Was No Glycemic Threshold Regarding Progression of Retinopathy
- •Diabetic Ketoacidosis (DKA)
- •Efforts to Normalize Blood Glucose Are Associated with Weight Gain in People with Type 1 Diabetes
- •Connecting Peptide (C-Peptide) Responders Have Less Risk of Progression of Retinopathy
- •Effects of Improved Control on Retinopathy Were Sustained in the Long-Term
- •Quality of Life Measure
- •“Metabolic Memory”: A Phenomenon Producing a Long-Term Beneficial Influence of Early Metabolic Control on Clinical Outcomes
- •Need for a More Physiologic Glycemic Control Regimen
- •Effect of Intensive Insulin Therapy on Hypoglycemia Counterregulation
- •b Cell Function
- •Whole Pancreas Transplantation
- •Effect of SPK Transplantation on Diabetic Retinopathy
- •Islet Cell Transplantation
- •Adverse Effects of Chronic Immunosuppression
- •Effect of Islet Cell Transplantation on Retinopathy
- •References
- •Index
Visual Psychophysics in Diabetic Retinopathy |
83 |
Frost-Larsen et al. [83] demonstrated a close correlation of the oscillatory potential and nyctometry in IDDM patients, suggesting a common retinal mechanism responsible for the changes of both parameters in DR. Macular recovery function is a complex phenomenon consisting of photochemical, neural receptor, and network adaptation, the resultant achievement being an optimized interaction of all three mechanisms [88]. Although the mechanisms responsible for the increased recovery time in the initial phase of this test are unknown, the phenomenon appears related to disturbances primarily in the neural network adaptation. The site of the neuronal mechanisms of this test is likewise believed to be located to the inner nuclear layer, and it might be influenced by the same functional disturbances which suppress the generation of the oscillatory potential [83, 89]. Unfortunately, the technology to perform this test is no more available and a new electronic version is under investigation.
PERIMETRY
Perimetry represents a systematic measurement of visual field sensitivity function. It encompasses the assessment of differential light threshold of retinal locations from the fovea to the preplanned periphery. The two most commonly used types of perimetry are Goldmann kinetic perimetry and (threshold) static automated perimetry. Kinetic perimetry is particularly useful for obtaining the outline of extensive defects and identifying major scotomas. Static perimetry is particularly useful for detailed probing in carefully selected areas and represents the current cornerstone of visual field testing. Standard threshold static automated perimetry quantifies the differential light threshold required to detect a static white light stimulus in the visual field. Since standard threshold perimetry uses a static achromatic stimulus, it is thought to nonselectively evoke both major groups of retinal ganglion cells: (1) the parasol ganglion cells of the magnocellular visual pathway subserving motion perception, low spatial resolution, high contrast sensitivity, and stereopsis and (2) the midget ganglion cells of the parvocellular visual pathway subserving central visual acuity, color perception, low contrast sensitivity, high spatial resolution, static stereopsis, pattern recognition, and shape. There is considerable overlap in the receptive fields of these cell types; therefore, a nonselective, white-on-white stimulus cannot detect the earliest loss of retinal ganglion cells, and standard threshold perimetry therefore may not detect visual field loss until the whole population of retinal ganglion cells is significantly damaged. In addition to new algorithms, visual field testing is becoming more sophisticated with the development of new perimetric technologies. New technologies are aimed at earlier detection of subtle deficits and enhancing diagnostic accuracy. The sensitivity to short-wavelength stimuli can be measured in different regions of the visual field by blue-on-yellow perimetry (short-wavelength automated perimetry, SWAP). It is accomplished by determining the sensitivity to blue stimuli (thus stimulating the short-wavelength cone system) on a bright yellow background. In this way, longand medium-wavelength cone system sensitivity is reduced and rods are saturated.
In DME, visual acuity loss is quite relevant and irreversible when long lasting edema involves the center of the macula; in these cases, the outcome of laser treatment is poor. But before the loss of visual acuity is reported by patients, they may suffer from
84 |
Midena and Vujosevic |
other disturbances of visual function such as waviness, blurring, relative scotoma, and decrease of contrast sensitivity which are not assessed and quantified in routine examination. Therefore, a visual function test aimed at identifying vision-threatening retinopathy before visual acuity is affected would be of great value. One possible approach may be to identify decreased sensitivity in paracentral areas using perimetry.
It has been reported that patients with diabetic retinopathy show sensitivity loss in the midperipheral field by white-on-white perimetry (WWP) and that this sensitivity loss is correlated with the retinal areas of nonperfusion [90–92]. The sensitivity loss was closely associated with microangiopathy and was greater in the midperipheral area than in the paracentral area. Bek and Lund-Andersen evaluated with Humphrey Field Analyzer retinal sensitivity over cotton wool spots in patients with diabetic retinopathy and reported localized nonarcuate scotomata in the visual field, which may persist even when the funduscopic lesions resolve [93]. A selective loss of short-wavelength sensitive pathway has been demonstrated in diabetic patients with minimal or no diabetic retinopathy [94–97]. SWAP has been suggested as a useful tool for defining visual function loss in diabetic patients with early ischemic damage of the macula or clinically significant macular edema [98, 99]. Decreased blue-on-yellow sensitivity has also been demonstrated in diabetic children without clinically detectable retinopathy [100] (Table 3).
When comparing SWAP and WWP in diabetics, SWAP seems superior for macular localized field loss determination and early ischemic macular damage evaluation. Uncertainty remains about its use in macular edema. Moreover, SWAP showed to be highly lens opacity–dependent [98, 99, 101]. On the other hand, WWP correlates better with the ETDRS severity scale than SWAP or visual acuity determination, and it might be better in separating groups with different levels of retinopathy [102]. As elegantly stated by Sunness et al. [103], conventional visual field examination is inadequate for the accurate functional evaluation of macular diseases and detection of small scotoma, particularly when foveal function is compromised and the patient may have unstable and extrafoveal fixation. Accuracy of the conventional visual field rests on the assumption that fixation is foveal and stable. Moreover, the detection of the site and stability of retinal fixation (foveal or extrafoveal) and the quantification of retinal threshold over small and discrete retinal lesions are beyond the possibilities of conventional, automatic, and nonautomatic perimetry [2].
MICROPERIMETRY (FUNDUS-RELATED PERIMETRY)
The integration of retinal details with function has been achieved by fundus-related perimetry, more widely known as microperimetry. Microperimetry allows for the exact topographic correlation between fundus abnormalities and corresponding functional alterations by integration, with different methods, of differential light threshold (more commonly known as retinal sensitivity) and fundus imaging. It also allows to quantify fixation characteristics, by exactly defining location and stability of any foveal or extrafoveal (PRL, preferred retinal locus) fixation site, as well as determination of size, site, and shape of scotoma. Moreover, the possibility of an automatic follow-up examination (using the microperimeter MP-1, Nidek Co, Japan) which allows the evaluation of exactly the same retinal points tested at baseline, regardless of any change in fixation
Table 3. Studies which have investigated perimetry in patients with diabetic retinopathy
|
Principal |
|
|
|
|
|
|
|
|
investigator/ |
|
|
|
|
|
|
|
|
year of |
|
|
Age in years: |
|
Nature |
|
|
|
publication |
Types of study |
Sample size |
mean/range |
DR status and VA |
of stimulus |
Conclusions |
|
|
|
|
|
|
|
|
|
|
|
Bek et al. [136] |
Cross-sectional |
20 Pts |
– |
Hard exudates and/or |
Humphrey field |
No topographical correlation was |
|
|
|
|
|
|
localized leakage of |
analyzer |
found between barrier leakage |
|
|
|
|
|
|
fluorescein |
|
and decreased light sensitivity |
|
|
|
|
|
|
VA: 6/18 or better |
|
|
|
|
Lutze et al. |
Case-control |
Cases-31 pts |
30 (Median) |
No DR-6 |
Humphrey field |
S-cone sensitivity and achromatic |
|
|
[137] |
|
Controls-50 pts |
(19–59) |
Mild retinopathy-10 |
analyzer |
sensitivity were not significantly |
|
|
|
|
|
|
Moderate retinopathy-4 |
|
reduced in diabetic pts, but they |
|
|
|
|
|
|
Severe retinopathy-4 |
|
showed localized sensitivity |
|
|
|
|
|
|
PDR-7 |
|
losses in visual fields in diabetic |
|
|
|
|
|
|
VA: 20/80 or better |
|
pts. Localized sensitivity losses |
|
|
|
|
|
|
|
|
of SWAP were significantly cor- |
|
|
|
|
|
|
|
|
related to the level of DR |
|
|
Hudson et al. |
Case-control |
Cases-24 pts |
59.75 (45–75) |
CSME (Early Treatment |
Humphrey field |
SWAP test showed greater sensitiv- |
|
|
[99] |
|
and eyes |
48 (18–84) |
Diabetic Retinopathy |
analyzer |
ity than WWP test in detecting |
|
|
|
|
Controls-400 |
|
Study (ETDRS)) |
|
visual field defects. The position |
|
|
|
|
pts |
|
VA: 0.25 or better |
|
of localized field loss assessed by |
|
|
|
|
|
|
|
|
SWAP corresponded with clinical |
|
|
|
|
|
|
|
|
mapping of the area of DME |
|
|
Nomura et al. |
Case-control |
Cases-31 pts |
Cases: No |
No DR-21 |
Humphrey field |
No significant correlation was found |
|
|
[138] |
|
Controls-11 pts |
DR 50.9 |
bDR-10 |
analyzer 750 |
between level of DR and FM 100 |
|
|
|
|
|
(40–59) |
VA: 20/20 |
|
Hue Test. The SWAP sensitivity |
|
|
|
|
|
bDR 51.3 |
|
|
of the upper half of the central |
|
|
|
|
|
(40–59) |
|
|
20–30° area was significantly |
|
|
|
|
|
Controls: 51.7 |
|
|
reduced in bDR group; no signifi- |
|
|
|
|
|
(40–59) |
|
|
cant sensitivity loss was detected |
|
|
|
|
|
|
|
|
with WWP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(continued) |
|
Table 3. (continued)
Principal |
|
|
|
|
|
|
investigator/ |
|
|
|
|
|
|
year of |
|
|
Age in years: |
|
Nature |
|
publication |
Types of study |
Sample size |
mean/range |
DR status and VA |
of stimulus |
Conclusions |
|
|
|
|
|
|
|
Remky et al. |
Case-control |
Cases-31 pts |
35 ± 12 |
No DR-9 |
Humphrey field |
SWAP thresholds were significantly |
[98] |
|
and eyes |
|
Only microaneurysms-5 |
analyzer 750 |
correlated with increasing size of |
|
|
Controls-31 |
|
Mild retinopathy-13 |
|
FAZ and PIA; WWP thresholds |
|
|
|
|
Moderate retinopathy-1 |
|
and VA were not correlated with |
|
|
|
|
Severe retinopathy-2 |
|
diabetic changes of the perifoveal |
|
|
|
|
VA: 20/25 or better |
|
capillary area |
Verrotti [139] |
Prospective |
Cases-60 pts |
15.9 (14–18) |
No DR |
Humphrey field |
The probability of retinopathy devel- |
|
study |
|
|
VA: 1.0 or better |
analyzer 640 |
opment after 8 years of follow- |
|
|
|
|
|
|
up was significantly higher in |
|
|
|
|
|
|
subgroups of patients with mean |
|
|
|
|
|
|
sensitivity in areas 2 and 3 below |
|
|
|
|
|
|
cut-off |
Afrashi et al. |
Case-control |
Cases-43 pts |
31.03 (16–38) |
No DR |
Humphrey field |
There was no difference in sensi- |
[140] |
|
Controls-30 pts |
30.13 (21–35) |
VA: 20/20 |
analyzer 750 |
tivity between the diabetic and |
|
|
|
|
|
|
the control group. The values |
|
|
|
|
|
|
of mean deviation by blue-on- |
|
|
|
|
|
|
yellow perimetry in diabetic pts |
|
|
|
|
|
|
were significantly higher than in |
|
|
|
|
|
|
the control group. WWP did not |
|
|
|
|
|
|
show this difference |
Remky et al. |
Case-control |
Cases-45 pts |
37.2 ± 10.4 |
No/mild macular |
Humphrey field |
SWAP thresholds were signifi- |
[141] |
|
and eyes |
37.2 ± 14.1 |
changes (not edema) |
analyzer 750 |
cantly more reduced in pts with |
|
|
Controls-58 pts |
|
No DR-13 |
|
advanced DR than those of |
|
|
|
|
Only microaneu- |
|
WWP. In pts with no DR sensi- |
|
|
|
|
rysms-11 |
|
tivity was not affected |
|
|
|
|
Advanced DR-21 |
|
|
|
|
|
|
Cases-VA: 0.015 ± 0.042 |
|
|
|
|
|
|
Controls-VA: |
|
|
|
|
|
|
0.013 ± 0.034 |
|
|
Han et al. [142] |
Case-control |
Cases-22 pts |
52.4 (32–59) |
Cases-mild (20) or mod- |
Humphrey field |
Both groups showed reduced sensi- |
|
|
and eyes |
43.5 (26–64) |
erate (2) DR |
analyzer |
tivity at SWAP test. Also mfERG |
|
|
Controls-18 pts |
|
Controls-no DR |
|
showed similar number of signifi- |
|
|
|
|
VA: 20/25 |
|
cant abnormalities. In diabetic pts |
|
|
|
|
|
|
with DR SWAP and mfERG also |
|
|
|
|
|
|
showed some spatial agreement |
Bengtsson et al. |
Cross-sectional |
59 Pts and eyes |
50.6 (20–69) |
– |
Humphrey field |
WWP was correlated with degree of |
[102] |
|
|
|
|
analyzer 750 |
peripheral DR better than VA or |
|
|
|
|
|
|
SWAP test. SWAP was superior |
|
|
|
|
|
|
to both WWP and VA in measur- |
|
|
|
|
|
|
ing effects caused by enlarged |
|
|
|
|
|
|
FAZ and PIAs |
Agardh et al. |
Cross-sectional |
59 Pts and eyes |
50.6 (20–69) |
DME-20 |
Humphrey field |
VA was correlated to the thickness |
[101] |
|
|
|
No DME-39 |
analyzer 750 |
of macula when edema involved |
|
|
|
|
VA: −0.04 (median) |
|
the center of the macula. SWAP |
|
|
|
|
(−0.22 to +0.82) |
|
was able to detect macular |
|
|
|
|
|
|
edema, WWP was not. SWAP |
|
|
|
|
|
|
and WWP were correlated to |
|
|
|
|
|
|
FAZ and PIA. Visual field defects |
|
|
|
|
|
|
reflected ischemic damage of |
|
|
|
|
|
|
the macula rather than macular |
|
|
|
|
|
|
edema per se |
|
|
|
|
|
|
|
|
|
|
|
|
|
(continued) |
Table 3. (continued)
Principal |
|
|
|
|
|
|
investigator/ |
|
|
|
|
|
|
year of |
|
|
Age in years: |
|
Nature |
|
publication |
Types of study |
Sample size |
mean/range |
DR status and VA |
of stimulus |
Conclusions |
|
|
|
|
|
|
|
Nitta et al. [143] |
Case-control |
Cases-33 pts |
41.7 ± 6.8 |
No DR |
Humphrey field |
There was a correlation between |
|
|
and eyes |
41.2 ± 6.3 |
VA: 20/20 or better |
analyzer 750 |
decreasing of mean deviation and |
|
|
Controls-33 |
|
|
|
increasing clinical data (duration |
|
|
|
|
|
|
of diabetes, fructosamine concen- |
|
|
|
|
|
|
tration, glycatet hemoglobin) with |
|
|
|
|
|
|
SWAP test, with not in WWP test |
Lobefalo et al. |
Case-control |
Cases-50 pts |
13.3 (10.1– |
No DR |
Humphrey field |
Mean perimetric sensitivity of |
[100] |
|
(100 eyes) |
16.3) |
VA: 0.8 or better |
analyzer 640 |
SWAP showed significant lower |
|
|
Controls: 50 |
|
|
|
values in micro-albuminuric |
|
|
pts |
|
|
|
group than values of normo-albu- |
|
|
|
|
|
|
minuric group. Mean perimetric |
|
|
|
|
|
|
sensitivity of WWP did not show |
|
|
|
|
|
|
significant differences between |
|
|
|
|
|
|
micro-albuminuric and normo- |
|
|
|
|
|
|
albuminuric diabetic pts, either |
|
|
|
|
|
|
between diabetic pts and controls |
Pahor [144] |
Case-control |
Cases-32 eyes |
51.2 (22–71) Moderate DR-17 eyes |
Humphrey field |
There was a significant correlation |
|
|
|
(25 pts) |
48.3 (17–64) |
Severe DR-15 |
analyzer |
between visual field defects and |
|
|
Controls-30 |
|
VA: 6/9 or better |
|
areas of reduced retinal perfusion |
|
|
eyes |
|
|
|
|
|
|
|
|
|
|
|
Pts patients; DR diabetic retinopathy; VA visual acuity; bDR background diabetic retinopathy; PDR proliferative diabetic retinopathy; CSME clinically significant diabetic macular edema; DME diabetic macular edema; FAZ foveal avascular zone; PIA Perifoveal Intercapillary Area; WWP white-on-white perimetry; SWAP short-wavelength automated perimetry; mfERG multifocal electroretinogram
Visual Psychophysics in Diabetic Retinopathy |
89 |
characteristics, is a valuable tool of this technique, mainly in the evaluation of treatment outcome. Microperimetry offers several advantages vs. standard perimetry in the quantification of macular sensitivity, such as direct real-time fundus control, direct correlation between sensitivity and fundus details, detection of central microscotomata, and continuous monitoring of fixation.
The original Scanning Laser Ophthalmoscope (SLO, Rodenstock, Germany) was the first instrument combining static perimetric testing and simultaneous observation of the fundus. SLO allowed a real-time examination by an infrared (IR) source of the retina and allowed the manual projection of visual stimuli of different shapes, sizes, and intensities over selected retinal areas. The sensitivity map, obtained according to the stimulation pattern (in dB or pseudocolors), was available at the end of the examination. This map contained the fixation area, the fixation target, and the threshold data. This instrument is no more commercially available.
With the introduction of a new microperimeter, a liquid crystal display (LCD) microperimeter (MP-1) coupled with a color fundus camera, visualization of color fundus details allows to directly report functional data onto clinical fundus image, and automatic tests are also obtained. MP-1 microperimeter has both an infrared and a color fundus camera, as well as an automatic real-time tracking system that allows for a full automatic retinal fixation and threshold determination as well as automatic follow-up and differential maps determination, independently from fixation characteristics. The main technical characteristics of this instrument have been previously described in detail [104–106]. Rohrschneider et al. compared MP-1 and SLO microperimeters and found that both instruments analyzed retinal sensitivity and fixation characteristics, and the results obtained from both instruments were directly comparable. However, MP-1 is superior to SLO due to the automatic real-time alignment system, a larger field of (fundus) view (44° × 36° MP-1 vs. 33° × 2° SLO) and color image [107].
The most relevant characteristics of advanced microperimetry performed with the MP-1 microperimeter may be briefly summarized as follows:
•Exact fundus-related stimulation
•Automatic eye-tracking system
•Automatic static and kinetic stimulation (with standardized or customized grids and centration)
•Normative age-related database [108]
•Age-related differential maps (local defect determination, shallow defects determination, etc.)
•Automatic follow-up and differential maps
•Screening tests (short test duration: <5 min)
•Morpho/functional relationship investigation (overlapping of sensitivity maps over different types of fundus images)
MP-1 microperimetry is a mesopic test that requires a 5–10-min dark light adaptation before starting the examination.
In the last 15 years, microperimetry has been successfully used in the diagnosis and follow-up of different macular disorders, including: age-related macular degeneration, myopic maculopathy, macular dystrophies, and diabetic macular edema [105, 109–117].
90 |
Midena and Vujosevic |
Fig. 1. Microperimetry map (in decibels) superimposed onto the color fundus image in a case of clinically significant diabetic macular edema (CSME). Decrease of retinal sensitivity is shown on the temporal side of the macular region.
In DME, microperimetry has been used for the quantification of macular sensitivity; the correlation of macular sensitivity to macular thickness, visual acuity, and fundus autofluorescence data; and the fixation patterns determination in different stages and types of edema.
Different studies report the correlation between retinal sensitivity, determined with microperimetry, and VA in patients with CSME [102, 108, 118]. Moreover, reduced retinal sensitivity is related to increasing retinal thickness [102, 114, 118] (Table 4). In a study published by Vujosevic et al. [104], a significant inverse relationship was found in patients with CSME, between retinal sensitivity and normalized retinal thickness values obtained with OCT, with a decay of 0.83 dB (p < 0.0001) for every 10% of deviation of retinal thickness from the normal values (Fig. 1). This means that normalized macular thickness better copes with macular function than any absolute value [104]. Microperimetry seems to represent a better functional testing than BCVA for quantifying visual function in diabetic patients, because it incorporates a functional measure that may potentially supplement the predictive value of OCT and visual acuity [104, 118, 119].
Besides retinal sensitivity, microperimetry allows to quantify retinal fixation characteristics. Fixation characteristics (location and stability) are relevant parameters for understanding patient’s quality of vision, especially reading ability, and its knowledge may be important in planning laser treatment [110, 119–121]. Reading ability better correlates with subjective quality of vision rather than distant visual acuity [110]. Whereas different studies agree that macular sensitivity deteriorates in patients with DME, data about fixation characteristics are quite contrasting [104, 109, 110, 114, 118, 122] (Table 4). Kube et al. [114] found decreased fixation stability in patients with DME using SLO microperimetry. Carpineto et al. [122] found that all eyes with eccentric or unstable fixation had cystoid DME. Vujosevic et al. [119] found that fixation patterns are not significantly
Table 4. Studies which have investigated microperimetry in patients with diabetic retinopathy
|
Principal |
|
|
|
|
|
|
|
investigator/ |
|
|
|
|
|
|
|
year of |
|
Sample |
Age in years: |
|
Nature |
|
|
publication |
Types of study |
size |
mean/range |
DR status and VA |
of stimulus |
Conclusions |
|
|
|
|
|
|
|
|
|
Rohrschneider |
Prospective |
30 Pts and |
63 (37–81) |
CSME |
SLO 101 |
In ten eyes VA significantly improved |
|
et al. [110] |
|
eyes |
|
VA: From 20/200 to |
Rodenstock |
after laser photocoagulation, in nine |
|
|
|
|
|
20/20 |
|
eyes it decreased. Fifteen eyes showed |
|
|
|
|
|
|
|
improving in mean light sensitivity |
|
|
|
|
|
|
|
after treatment, seven showed decreas- |
|
|
|
|
|
|
|
ing. Nine eyes improved in fixation |
|
|
|
|
|
|
|
stability, five eyes demonstrated a |
|
|
|
|
|
|
|
deterioration. There was no significant |
|
|
|
|
|
|
|
correlation between stability of fixa- |
|
|
|
|
|
|
|
tion and visual acuity or subjective |
|
|
|
|
|
|
|
patient changes |
|
Mori et al. |
Cross- |
19 Pts and |
63 (45–78) |
CSME with: |
SLO 101 |
Significant difference was found between |
|
[111] |
sectional |
eyes |
|
Dense scotoma-4 |
Rodenstock |
the three groups VA. There were sig- |
|
|
|
|
|
Relative scotoma-10 |
|
nificant differences in the prevalence |
|
|
|
|
|
No scotoma-5 |
|
of cystoid changes, diffuse edema, |
|
|
|
|
|
VA: 0.7 (−0.2 to 2) |
|
unstable fixation among the three |
|
|
|
|
|
logMAR |
|
groups. Group with dense scotoma |
|
|
|
|
|
|
|
showed a great association with all |
|
|
|
|
|
|
|
these three clinical characteristics, |
|
|
|
|
|
|
|
group with no scotoma did not show |
|
|
|
|
|
|
|
any of these characteristics |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(continued) |
Table 4. (continued)
Principal |
|
|
|
|
|
|
investigator/ |
|
|
|
|
|
|
year of |
|
Sample |
Age in years: |
|
Nature |
|
publication |
Types of study |
size |
mean/range |
DR status and VA |
of stimulus |
Conclusions |
|
|
|
|
|
|
|
Moller and |
Prospective |
24 Pts and |
66.9 (38–85) |
CSME treated with |
SLO 101 |
A significant negative correlation was |
Bek [145] |
|
eyes |
|
standard argon |
Rodenstock |
found between the changes in VA and |
|
|
|
|
laser treatment |
|
the changes in the retinal areas covered |
|
|
|
|
(ETDRS protocol) |
|
by hard exudates. In four pts hard exu- |
|
|
|
|
VA: |
|
dates covered fovea at baseline, and |
|
|
|
|
I group: −0.05 |
|
the site of fixation was at the border of |
|
|
|
|
to 0.2 |
|
the exudate. After laser treatment, in |
|
|
|
|
II group: 0.21–0.4 |
|
two eyes hard exudates reduced, result- |
|
|
|
|
III group: 0.41–0.6 |
|
ing in an increased VA and a shift of |
|
|
|
|
IV group: 0.61–0.8 |
|
the site of fixation, in one eye hard |
|
|
|
|
|
|
exudates increased, followed by a VA |
|
|
|
|
|
|
impairment and a more peripheral site |
|
|
|
|
|
|
of fixation |
Kube et al. |
Case-control |
Cases-27 |
54 (17–81) |
Presence of diabetic |
SLO 101 |
Fixation stability was significantly |
[114] |
|
pts |
45 (18–85) |
maculopathy |
Rodenstock |
decreased in diabetic pts in comparison |
|
|
Controls-61 |
|
Cases-VA: 0.6 ± 0.32 |
|
to controls. Macular light sensitivity |
|
|
|
|
Controls-VA 1.0 ± 0.1 |
|
was worse in diabetic pts than in con- |
|
|
|
|
|
|
trols, and temporal parts of the macula |
|
|
|
|
|
|
were the most affected. No correlation |
|
|
|
|
|
|
was found between VA and foveal |
|
|
|
|
|
|
light sensitivity nor foveal fixation |
Vujosevic |
Cross- |
61 Eyes |
56.1 ± 12.5 |
Non edema (NE)-16; |
MP-1 Nidek |
VA and central macular sensitivity cor- |
et al. [104] |
sectional |
(32 pts) |
|
VA: −0.07 ± 0.18 |
|
related significantly in the NCSME |
|
|
|
|
logMAR |
|
group, but not in the NE or in the |
|
|
|
|
NCSME-30; VA: |
|
CSME group. There was a significant |
|
|
|
|
0.12 ± 0.48 |
|
correlation between retinal sensitiv- |
|
|
|
|
CSME-15; VA: |
|
ity and normalized macular thickness |
|
|
|
|
0..33 ± 0.36 |
|
detected by OCT scans |
Okada et al. |
Retrospective |
Cases-32 |
Cases-58.8 |
CSME |
MP-1 Nidek |
Mean sensitivities in diabetic pts were |
[118] |
case-con- |
eyes (25 |
(25–76) |
VA: 0.7 (0.1–0.7) |
|
lower than in healthy controls. VA and |
|
trol |
pts) |
Controls-42–76 |
Controls: −0.1 (−0.2 |
|
macular sensitivities were significantly |
|
|
Controls-17 |
|
to −0.1) |
|
correlated. A significant negative cor- |
|
|
pts |
|
|
|
relation was also found between foveal |
|
|
|
|
|
|
thickness (by OCT) and the mean reti- |
|
|
|
|
|
|
nal sensitivities at central 2° and 10° |
Carpineto |
Cross- |
Cases: 84 |
66.35 (45–81) |
CSME (67% cystoid) |
MP-1 Nidek |
VA, central retinal sensitivity, foveal |
et al. [122] |
sectional |
pts and |
|
VA: 0.60 ± 0.29 log- |
|
thickness, duration of symptoms, |
|
|
eyes |
|
MAR |
|
HbA1c levels and the presence of cyst- |
oid macular edema were significantly associated with fixation impairment. The three groups (stable vs. unstable and central vs. eccentric fixation) showed statistically differences in VA, central retinal sensitivity, and foveal thickness. Cystoid macular edema was significantly more frequent in the eccentric and unstable group
(continued)
Table 4. (continued)
Principal |
|
|
|
|
|
|
investigator/ |
|
|
|
|
|
|
year of |
|
Sample |
Age in years: |
|
Nature |
|
publication |
Types of study |
size |
mean/range |
DR status and VA |
of stimulus |
Conclusions |
|
|
|
|
|
|
|
Unoki et al. |
Prospective |
20 Eyes |
62.9 (43–78) |
Severe NPDR-11 |
MP-1 Nidek |
Areas of capillary nonperfusion detected |
[146] |
cross-sec- |
(17 pts) |
|
PDR-9 |
|
by FA were associated with the loss of |
|
tional |
|
|
All showed a nonper- |
|
retinal sensitivity. The average sensitivity |
|
|
|
|
fused area in the |
|
of the next nearest points from the area of |
|
|
|
|
temporal macula |
|
capillary nonperfusion was significantly |
|
|
|
|
VA: 0.28 ± 0.30 log- |
|
reduced compared with that of the other |
|
|
|
|
MAR |
|
areas. OCT scans showed morphological |
|
|
|
|
|
|
changes of the nonperfused areas |
Grenga et al. |
Prospective |
20 Eyes |
65.7 ± 13.3 |
Chronic diffuse macu- |
MP-1 Nidek |
Three months after injection of intravitreal |
[147] |
|
|
|
lar edema |
|
triamcinolone, VA, macular thickness |
|
|
|
|
VA: 0.13 ± 0.09 deci- |
|
and mean retinal sensitivity improved |
|
|
|
|
mal units |
|
significantly. At 6 months after injection |
|
|
|
|
|
|
follow-up of the data were similar to |
|
|
|
|
|
|
those at baseline |
Vujosevic |
Prospective |
179 Eyes |
58.4 ± 11.2 |
NCSME-32 |
MP-1 Nidek |
Site and stability of fixation were associ- |
et al. [119] |
|
(98 pts) |
|
CSME-147 |
|
ated. A significant association was |
|
|
|
|
VA: from worse than |
|
found between fixation characteristics |
|
|
|
|
20/200 to 20/25 or |
|
and visual acuity, but they were not |
|
|
|
|
better |
|
influenced by edema characteristics |
|
|
|
|
|
|
(diffuse, focal, cystoid, spongelike |
|
|
|
|
|
|
edema, with or without neuroretinal |
|
|
|
|
|
|
detachment). Subfoveal hard exudates |
|
|
|
|
|
|
were significantly associated with |
|
|
|
|
|
|
eccentric and unstable fixation, juxta- |
|
|
|
|
|
|
foveal or no exudates were not |
|
|
|
|
|
|
|
Pts patients; VA visual acuity; DR diabetic retinopathy; PDR proliferative diabetic retinopathy; NPDR non-proliferative diabetic retinopathy; CSME clinically significant diabetic macular edema; SLO scanning laser ophthalmoscope; MP-1 Microperimeter MP-1
Visual Psychophysics in Diabetic Retinopathy |
95 |
Fig. 2. Microperimetry map (in decibels) superimposed onto the color fundus image in a case of severe CSME with large hard exudates. Over hard exudates the retina shows some dense scotomatous zones. Fixation (tiny light blue spots centred onto the fovea) is stable and central.
influenced by either topographical extension of edema (focal or diffuse) or by the OCT classification of edema. Moreover, fixation pattern was not significantly influenced by the presence of subfoveal serous neuroretinal detachment, showing a different fixation behavior compared to age-related macular degeneration [105, 119]. The only parameter influencing fixation was the presence of subfoveal hard exudates. In these cases, the knowledge of fixation location and stability is fundamental in order to avoid complications due to the photocoagulation of newly developed fixation area (Fig. 2).
The duration of DME, which cannot be exactly quantified in a cross-sectional study, might have a relevant impact on the survival and/or functional reserve of macular cells undergoing mechanical and toxic stress induced by edema, and this may explain the difference in fixation results described above. It seems that in patients with DME, the damage to photoreceptor occurs as a late phenomenon and probably is not related to intraretinal cysts formation. In diabetic retinopathy, retinal neurodegeneration may precede photoreceptor loss, as previously reported [123].
Therefore, microperimetry may be of value in predicting the functional outcome of DME after interventions that seem equally effective in restoring normal foveal thickness. This hypothesis has been recently confirmed by a randomized and prospective study conducted by Vujosevic et al. [124]. These authors have demonstrated that subthreshold micropulse diode laser is as effective as modified ETDRS photocoagulation in reducing central retinal thickness. But with subthreshold treatment, retinal macular sensitivity stabilizes or improves, whereas with standard photocoagulation, it significantly deteriorates, manifesting as progressive microscotomata.
